Open Access
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
Ying Gao, Yuesong Pan, Shangrong Han, Weiqi Chen, Jing Jing, Chunjuan Wang, Yingying Yang, Tingting Wang, Xia Meng, Xingquan Zhao, Liping Liu, Hao Li, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Yongjun Wang, Yilong Wang
DOI: 10.1136/svn-2022-002084 Published 23 June 2023
Ying Gao
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Yuesong Pan
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Shangrong Han
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Weiqi Chen
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Jing Jing
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Chunjuan Wang
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Yingying Yang
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Tingting Wang
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Xia Meng
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Xingquan Zhao
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Liping Liu
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Hao Li
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
S Claiborne Johnston
3
Dean's Office, Dell Medical School, University of Texas at Austin, Austin, Texas, USA
Pierre Amarenco
4
Department of Neurology and Stroke Center, Assistance Publique-Hôpitaux de Paris (APHP), Bichat Hospital, INSERM LVTS-U1148, University of Paris, Paris, France
5
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
Philip M Bath
6
Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK
Yongjun Wang
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
7
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
8
National Center for Neurological Diseases, Beijing, China
9
Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China
Yilong Wang
1
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
7
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
8
National Center for Neurological Diseases, Beijing, China
10
Chinese Institute for Brain Research, Beijing, China

Submit a Response to This Article
No eLetters have been published for this article.
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
Ying Gao, Yuesong Pan, Shangrong Han, Weiqi Chen, Jing Jing, Chunjuan Wang, Yingying Yang, Tingting Wang, Xia Meng, Xingquan Zhao, Liping Liu, Hao Li, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Yongjun Wang, Yilong Wang
Stroke and Vascular Neurology Jun 2023, 8 (3) 249-258; DOI: 10.1136/svn-2022-002084

Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
Ying Gao, Yuesong Pan, Shangrong Han, Weiqi Chen, Jing Jing, Chunjuan Wang, Yingying Yang, Tingting Wang, Xia Meng, Xingquan Zhao, Liping Liu, Hao Li, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Yongjun Wang, Yilong Wang
Stroke and Vascular Neurology Jun 2023, 8 (3) 249-258; DOI: 10.1136/svn-2022-002084
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
Ying Gao, Yuesong Pan, Shangrong Han, Weiqi Chen, Jing Jing, Chunjuan Wang, Yingying Yang, Tingting Wang, Xia Meng, Xingquan Zhao, Liping Liu, Hao Li, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Yongjun Wang, Yilong Wang
Stroke and Vascular Neurology Jun 2023, 8 (3) 249-258; DOI: 10.1136/svn-2022-002084